Goldman Sachs’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Goldman Sachs’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,000	Closed	-$86K	–	7683
2015 Q4	$86K	Buy	+5,000	New	+$119K	﹤0.01%	6265
2015 Q2	–	Sell	-9,180	Closed	-$719K	–	7712
2015 Q1	$719K	Sell	9,180 -4,100	-31%	-$254K	﹤0.01%	4781
2014 Q4	$805K	Sell	13,280 -10,760	-45%	-$540K	﹤0.01%	4814
2014 Q3	$1.02M	Buy	+24,040	New	+$1.29M	﹤0.01%	4588
2014 Q1	–	Sell	-20,000	Closed	-$1.13M	–	7159
2013 Q4	$1.13M	Buy	+20,000	New	+$1.12M	﹤0.01%	4639

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs's OREX Position: Q4 2017 in Review

Goldman Sachs sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 17,336 shares — an estimated $37K sold.

Goldman Sachs first reported a position in OREX in Q2 2013 and held it in 18 quarters. The position peaked at $4.5M in Q3 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

Goldman Sachs reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Goldman Sachs sold 17,336 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $37K.
Goldman Sachs first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
Goldman Sachs's Orexigen Therapeutics, Inc. position peaked at $4.5M in Q3 2014.
41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.